TMC launches cancer-focused partnership with Japan

global collaboration

The partnership between Japan-based Mitsui Fudosan Co. Ltd. and the National Cancer Center will focus on advancing cancer treatments, providing a pathway for Japanese innovators to expand in the U.S. market. Photo courtesy of TMC

Houston's Texas Medical Center announced the launch of its new TMC Japan BioBridge and Japan-Accelerator Cancer Therapeutics and Medical Devices, or JACT, this month.

The strategic partnership between Japan-based Mitsui Fudosan Co. Ltd. and the National Cancer Center will focus on advancing cancer treatments and providing a pathway for Japanese innovators to expand in the U.S. market. A delegation from TMC recently visited Tokyo, and William F. McKeon, president and CEO of TMC, signed the TMC Japan BioBridge Memorandum of Understanding with Takeshi Ozane, general manager of Mitsui Fudosan, and Hitoshi Nakagama, president of the National Cancer Center of Japan.

“The launch of TMC Japan BioBridge is a vital step forward in connecting two global leaders in healthcare innovation,” McKeon says in a statement. “Japan’s leadership has demonstrated an impressive commitment to advance medical cures and life sciences technologies and through this partnership, we are opening necessary doors for Japanese researchers and innovators to access the US market and collaborate with our TMC ecosystem. Together, we aim to accelerate critical breakthroughs to make a difference for patients all around the world.”

The new JACT will offer cancer-treatment companies a structured process to prepare for a U.S. expansion and will allow for meetings with pharmaceutical companies, hospital systems and investors and provide insights on U.S. regulatory approvals. It'll focus on three key areas, according to the statement:

  1. Milestone development and financial planning
  2. Clinical and regulatory expertise
  3. Strategic partnerships and market insights

“This TMC Japan BioBridge and JACT Program will enable us to promote the advancement of start-up companies aiming to commercialize innovative medical technologies originating in Japan into the U.S." Nakagama says in a statement. "We also hope this collaboration will not be limited to our (Japan Agency for Medical Research and Development)-supported project, but will lead to further cooperation between TMC, NCC, and other Japanese institutions in various fields.”

This is the sixth international strategic partnership for the TMC. It launched its first BioBridge, which focus on partnerships to support international healthcare companies preparing for U.S. expansion, with the Health Informatics Society of Australia in 2016. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.

From Your Site Articles
The Texas Medical Center visited the Netherlands to secure a deal that creates a BioBridge to the country and Houston. Photo courtesy of TMC

TMC again expands global impact with new Netherlands partnership

breaking news

The Texas Medical Center may be based in Houston, but the organization has again grown its global impact.

Since 2016, TMC’s BioBridges have worked with 88 startup companies. Those include strategic alliances with four other countries. Australia, the United Kingdom, Denmark and Ireland are all among TMC’s BioBridges partners. As of today, add the Netherlands to that list.

On September 27, TMC president and CEO, William F. McKeon, and Carmen van Vilsteren, chair of Health~Holland, Top Sector Life Sciences & Health (LSH), signed an agreement in Rotterdam. The TMC Netherlands BioBridge Memorandum of Understanding codifies the innovative goals of the partnership. Essentially, the BioBridge program provides a means for entrepreneurs, researchers, clinicians and industry partners from other countries to access the US market, as well as TMC experts.

“The TMC Netherlands BioBridge represents an unparalleled opportunity for collaboration and growth,” Ashley McPhail, chief external affairs & administration officer at Texas Medical Center said in a press release. “The Netherlands has solidified its position as a global leader in the field of life sciences and health, with a thriving ecosystem of research institutions, innovative companies, and highly skilled professionals. This strategic partnership will bring positive benefits to patients, clinicians and industry partners on a global scale.”

This lifeline for international healthcare companies makes expansion into the United States far smoother. The Global Innovators Launch Pad allows for startup founders to take part in a 10-week residency at the TMC Innovation Factory that will teach them about foundational infrastructure, clinical evidence and funding in the US.

“Since Texas is an important hub for innovation in the MedTech and digital health sectors, the collaboration with Texas Medical Center creates opportunities for Dutch companies looking to expand their international reach. Vice versa, it gives companies in Texas access to the vibrant Dutch Life Sciences & Health sector,” said van Vilsteren.

That exchange includes members of the TMC gaining the opportunity to participate in the Health~Holland Visitors Programme (HVP), “Shaping the Healthcare of the Future.”

The annual event invites high-level representatives from the private sector, NGOs, knowledge institutions, healthcare providers and different tiers of government to share their expertise.

It's the fifth partnership of its kind for TMC, with the last one being with Ireland, announced last year. TMC's other global initiatives include accelerators with Denmark and the United Kingdom, both announced earlier this year.

A new program established at TMC in partnership with Denmark will support the growth of three health tech companies. Photo courtesy of TMC

TMC launches co-hosted health tech accelerator with Denmark

biobridge support

Years ago, the Texas Medical Center established a biobridge to exchange technology and support with Denmark. Now, the two organizations are coming together to advance three health tech startups through a unique accelerator.

TMC and Denmark-based BioInnovation Institute announced today that three companies from BII will join a customized accelerator program that will guide them toward a United States go-to-market strategy. The program will be built off of the TMCi Health Tech Accelerator program.

“At TMC, we are elevating our ability to create curated go-to-market experiences for hand-selected companies that have a relationship with our partners at the BioInnovation Institute and that are seeking to prepare for of market expansion in the U.S.,” says Emily Reiser, associate director of TMC Innovation, in a news release. “We are excited about the opportunity to collaborate with BII and these founders.”

The three startups will head to Houston next week and incubate for six months, working with TMCi advisers and mentors on their individual challenges within commercialization and U.S. expansion. The three companies in the program are:

  • Aiomic, which is developing Aiomic360, an AI platform for postoperative complications. "With automated tracking and real-time risk assessment, Aiomic360 will function as a quality management tool for hospitals, a decision support tool for healthcare practitioners, and an individualized patient empowerment tool for surgical candidates," per the release.
  • Also tapping into AI, Orbit Health's solution, Neptune, is using motion data from smartwatches to track Parkinson’s motor state and treatment response passively. "Its continuous and objective insights enable regular treatment personalization that is needed throughout the course of the disease to optimize patient outcomes and improve quality of life," reads the release.
  • HEI Therapeutics is enabling at-home hypothyroidism management. "The innovative solution includes a patented finger stick blood test and digital patient empowerment tools and aims to significantly reduce the share of patients that is poorly regulated with medication," according to the release.

The TMC and the Ministry of Foreign Affairs of Denmark launched the Biobridge in 2019. BII is a nonprofit organization with a few resources — the Bio Studio, Venture Lab, and Venture House — that support life science startups with resources and even funding of up to €3 million per projects and €1.8 million per company.

“As we strengthen our offering to support visionary healthcare innovators to develop products and solutions to address clear unmet needs, our partnership with Texas Medical Center allows BII startups to gain exposure to US market and ready themselves for US market entry. We are thrilled about this collaboration with the Texas Medical Center which is one of the largest life science ecosystems in the world,” says Tony Cheng-fu Chang, principal at BioInnovation Institute. “Through the customized accelerator program, these three healthcare startups will acquire critical insight to create field-ready plans for bringing their products and solutions to the US market.”

TMC President and CEO William McKeon and Denmark's Minister of Health Magnus Heunicke officially formed a partnership on October 1 in Copenhagen. Courtesy of TMC

Texas Medical Center enters into health innovation partnership with Denmark

Biobridge

In an effort to advance medical innovations, the Texas Medical Center and the Kingdom of Denmark have announced a collaboration.

The partnership is the third of its kind in TMC's BioBridge program, with the other two collaborations being with Australia in 2016 and the United Kingdom last year. In March, TMC hosted Her Royal Highness Crown Princess Mary of Denmark, which began the conversation that created the foundation of the arrangement, William McKeon, president and CEO of TMC, says in a news release. The two entities announced the program on October 1 in Copenhagen.

"Now, TMC and the Kingdom of Denmark officially align each entity's respective startup ecosystems and will further accelerate the global pace of clinical research by fostering collaboration between academic researchers within the Texas Medical Center and at Denmark's esteemed institutions," McKeon says in the release.

The collaboration will focus on two areas — innovation and research and education, specifically within digital health, telemedicine, medical devices, and hospital operations.

"Denmark welcomes the significant potential of this trans-Atlantic BioBridge partnership with Texas Medical Center and its vast array of world class resources," says Magnus Heunicke, Denmark's minister of health and senior citizens, in the release. "Through this BioBridge, we build the foundation for the successful exchange of ideas, technologies, practices, and research that is at the center of breakthrough innovation and better healthcare globally."

Life science exports make up 17 percent of Denmark's total national exports — and that figure is expected to double by 2025, according to the release. The country is known for its quality data collection and is the second largest in Europe and measured in drugs per capita, per the release.

The Texas Medical Center's accelerator, TMCx, has had Danish companies as a part of the program. Sani nudge, which is based in Copenhagen, recently completed the program and, as a result, now has a Houston presence. Currently, Neurescue, also based in Copenhagen, is developing its computer-aided aortic occlusion catheter in the ongoing TMCx cohort.

"When HRH Crown Princess Mary visited the Texas Medical Center, she recognized the role of emerging technology in the advancement in health care in both of our nations," says McKeon at the announcement, according to the release. "Here in Copenhagen today at this momentous occasion, I am thrilled to formalize the BioBridge partnership that stands as tangible proof that we can always learn from our friends and colleagues around the world in our collective pursuit to advance care."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Intuitive Machines secures $175M equity investment to fuel growth

space funding

Houston-based space infrastructure and services company Intuitive Machines has secured a $175 million equity investment from unidentified institutional investors. The investors received shares of Class A stock in exchange for their funding.

Publicly held Intuitive Machines (Nasdaq: LUNR) says it plans to use the capital to help build revenue and invest in technology, including communications and data-processing networks.

“We are building a scalable infrastructure platform from low-Earth orbit to the moon and into deep space,” Intuitive Machines CEO Steve Altemus said in a news release. “With this investment, we can accelerate the integration of the combined company’s collective capabilities to deliver next-generation data, communications, and space-based infrastructure services.”

Intuitive Machines says the $175 million investment will improve its ability to secure deals for satellite systems, the proposed Golden Dome missile defense system and the proposed Mars telecommunications orbiter.

As the company pursues those deals, it’s seeking partners to develop space-based data centers.

The $175 million equity stake comes on the heels of Intuitive Machines completing its $800 million cash-and-stock purchase of Lanteris Space Systems. Intuitive Machines bought the satellite manufacturer from private equity firm Advent International.

In the third quarter, which ended Sept. 30, Intuitive Machines posted a $10 million net loss on revenue of $52.4 million.

Rice to revolutionize lymphatic disease research and more news to know

Trending Topics

Editor's note: We're looking back at the five biggest innovation headlines from the second half of February 2026, which include exciting Rice research advancements and Apple doubling down on production in Houston. Below are the five most-read InnovationMap stories from Feb. 16-28, 2026.

1. Rice University lands $18M to revolutionize lymphatic disease detection

Rice University scientists are pioneering two technologies to better diagnose and treat complex lymphatic anomalies. Photo via Getty Images.

An arm of the U.S. Department of Health and Human Services has awarded $18 million to scientists at Rice University for research that has the potential to revolutionize how lymphatic diseases are detected and help increase survivability. Continue reading.

2. Tech giant Apple doubles down on Houston with new production facility

Apple doubles down on Houston with new production facility, training centerPhoto courtesy Apple.

Tech giant Apple announced that it will double the size of its Houston manufacturing footprint as it brings production of its Mac mini to the U.S. for the first time. The company plans to begin production of its compact desktop computer at a new factory at Apple’s Houston manufacturing site later this year. The move is expected to create thousands of jobs in the Houston area, according to Apple. Continue reading.

3. Houston startup debuts new drone for first responders

Paladin Drones has revealed its next-gen emergency response drone, Knighthawk 2.0. Photo courtesy Paladin.

Houston-based Paladin Drones has debuted Knighthawk 2.0, its new autonomous, first-responder drone. The drone aims to strengthen emergency response and protect first responders, the company said in a news release. “We’re excited to launch Knighthawk 2.0 to help build safer cities and give any city across the world less than a 70-second response time for any emergency,” said Divyaditya Shrivastava, CEO of Paladin. Continue reading.

4. XSpace adds 3 Houston partners to fuel national expansion

XSpace, an innovative commercial real estate company, has partnered with three Houston firms to help grow its footprint. Rendering via xspacegroup.com

Texas-based XSpace Group has brought onboard three partners from the Houston area to ramp up the company’s national expansion. The new partners of XSpace, which sells high-end multi-use commercial condos, are KDW, Pyek Financial and Welcome Wilson Jr. Houston-based KDW is a design-build real estate developer, Katy-based Pyek offers fractional CFO services and Wilson is president and CEO of Welcome Group, a Houston real estate development firm. Continue reading.

5. Houston doctor wins NIH grant to test virtual reality for ICU delirium

Dr. Hina Faisal will test the effects of VR games on patients coming out the ICU, thanks to a recent NIH grant. Photo via Getty Images.

Think of it like a reverse version of The Matrix. A person wakes up in a hospital bed and gets plugged into a virtual reality game world in order to heal. While it may sound far-fetched, Dr. Hina Faisal, a Houston Methodist critical care specialist in the Department of Surgery, was recently awarded a $242,000 grant from the National Institute of Health to test the effects of VR games on patients coming out of major surgery in the intensive care unit (ICU). Continue reading.

Houston startup debuts bio-based 'leather' fashion collection in Milan

sustainable fashion

Earlier this month, Houston-based Rheom Materials and India’s conscious design studio Econock unveiled a collaborative capsule collection that signaled more than just a product launch.

Hosted at Lineapelle—long considered the global epicenter of the world's premier leather supply chain—in the vaulted exhibition halls of Rho-Fiera Milano, the collection centered around Rheom’s 91 percent bio-based leather alternative, Shorai.

It was a bold move, one that shifted sustainability from a concept discussed in panel sessions to garments that buyers could touch and wear.

The collection featured a bomber-style jacket, an asymmetrical skirt and a suite of accessories—all fabricated from Shorai.

The standout piece, a sculptural jacket featuring a funnel neck and dual-zip closure, was designed for movement, challenging assumptions about performance limitations in bio-based materials. The design of the asymmetrical skirt was drawn from Indian armored warrior traditions, according to Rheom, with biodegradable corozo fasteners.

Built as a modular wardrobe rather than isolated pieces, the collection reflects a shared belief between Rheom and Econock in designing objects that adapt to daily life, according to the companies.

The collection was born out of a new partnership between Rheom and Econock, focused on bringing biobased materials to the market. According to Rheom, the partnership solves a problem that has stalled the adoption of many next-gen textiles: supply chain friction.

While Rheom focuses on engineering scalable bio-based materials, New Delhi-based Econock brings the complementary design and manufacturing ecosystem that integrates artisans, circular materials and production expertise to translate the innovative material into finished goods.

"This partnership removes one of the biggest barriers brands face when adopting next-generation materials,” Megan Beck, Rheom’s director of product, shared in a news release. “By reducing friction across the supply chain, Rheom can connect brands directly with manufacturers who already know how to work with Shorai, making the transition to more sustainable materials far more accessible.”

Sanyam Kapur, advisor of growth and impact at Econock, added: “Our partnership with Rheom Materials represents the benchmark of responsible design where next-gen materials meet craft, creativity, and real-world scalability.”

Rheom, formerly known as Bucha Bio, has developed Shorai, a sustainable leather alternative that can be used for apparel, accessories, car interiors and more; and Benree, an alternative to plastic without the carbon footprint. In 2025, Rheom was a finalist for Startup of the Year in the Houston Innovation Awards.

Shorai is already used by fashion lines like Wuxly and LuckyNelly, according to Rheom. The company scaled production of the sugar-based material last year and says it is now produced in rolls that brands can take to market with the right manufacturer.

Houston startup debuts leather alternative fashion collection in Milan
View All Listings